<DOC>
	<DOCNO>NCT00303576</DOCNO>
	<brief_summary>Approximately 112 HIV-negative woman , age 18 50 , enrol multicenter study four site . Volunteers randomize dapivirine ( TMC120 ) vaginal gel match placebo gel . The volunteer receive investigational product total 42 day . Volunteers monitor day 7 , 28 42 safety , tolerability compliance .</brief_summary>
	<brief_title>A Safety Tolerability Study Dapivirine ( TMC120 ) Vaginal Microbicide Gel</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>HIVnegative Willing participate sign informed consent Willing test HIV , use experimental vaginal gel , randomize study group include possibility assign placebo group . Willing use two form contraception study . Willing undergo pelvic examination colposcopy photographic documentation accord protocol throughout study . Have regular menstrual cycle define minimum 21 day maximum 36 day menses . Willing abstain use vaginal product ( study product placebo ) . Willing sexually abstinent randomization completion Day 7 evaluation . Currently pregnant breastfeeding . Clinically detectable genital abnormality vulva , vaginal wall cervix . Laboratory confirm gonorrhea , chlamydia , trichomonas , syphilis , vaginal candidiasis clinically diagnose genital ulcer disease active HSV2 lesion . Breakthrough bleed gynecologic surgery within 60 day prior randomization . Symptomatic bacterial vaginosis unwilling undergo treatment . Women require treatment tuberculosis ( TB ) within 21 day prior randomization .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>